Paul Hastings LLP, a leading global law firm, announced today that the firm represented the shareholders of Paragon Biomedical, Inc., a full-service clinical research organization, in the successful sale of their shares to Clinipace, Inc., a digital contract research organization for emerging and mid-tier biopharmaceutical and medical device firms.

The terms of the transaction were not disclosed.

Paul Hastings M&A partner Rob Carlson led the Paul Hastings team, which also included Tax partner Douglas Schaaf and M&A associates Lisa Tran and Nasym Korloo.


Related Posts:

Leave a Reply